Sulfamethizole


Concise Prescribing Info
Indications/Uses
UTI.
Dosage/Direction for Use
Adult : PO 1.5-4 g/day in 3-4 divided doses.
Dosage Details
Oral
Urinary tract infections
Adult: 1.5-4 g/day in 3-4 divided doses.
Child: 30-45 mg/kg/day in 4 divided doses.
Renal Impairment
Dose reduction may be needed.
Hepatic Impairment
Dose reduction may be needed.
Contraindications
Severe renal or hepatic failure; blood disorders; hypersensitivity to sulfonamides; acute porphyria; SLE; infants ≤2 mth; pregnancy and lactation.
Special Precautions
Renal or hepatic impairment; history of allergy or asthma; AIDS; G6PD deficiency (at risk of haemolytic reactions); elderly; ensure adequate fluid intake to reduce risk of crystalluria. Discontinue if rash develops.
Adverse Reactions
Nausea, vomiting, anorexia, diarrhoea, hypersensitivity reactions, SLE, serum sickness-like syndrome, liver necrosis and hepatomegaly, myocarditis, pulmonary eosinophilia and fibrosing alveolitis, vasculitis, hypoglycaemia, hypothyroidism, neurological reactions, jaundice and kernicterus in premature neonates. Pseudomembranous colitis.
Potentially Fatal: Blood dyscrasias, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis.
Drug Interactions
Potentiates effects of oral anticoagulants, methotrexate, phenytoin. Increased risk of crystalluria with compounds that render the urine acidic. Increased risk of blood dyscrasias with clozapine. Increased risk of hypoglycaemia with tolbutamide.
Potentially Fatal: Increased risk of kidney damage with methenamine.
Lab Interference
Interfere with tests for urea, creatinine, urinary glucose and urobilinogen.
Action
Description: Sulfamethizole is a short-acting sulfonamide. It is generally not used in systemic infections due to low drug concentrations in blood and tissue.
Pharmacokinetics:
Absorption: Readily absorbed from GI tract.
Distribution: Protein-binding: 90%.
Metabolism: Undergoes slight acetylation.
Excretion: Half life: 1.5-3 hr. Rapidly excreted via urine.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Sulfamethizole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in